Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies

Jan A. Burger, MD, PhD, Susan O'Brien, Nathan Fowler, MD, Ranjana Advani, MD, Jeff Porte Sharman, MD, Richard R. Furman, MD, Raquel Izumi, PhD, Joseph Buggy, PhD, David Loury, PhD, Ahmed Hamdy, MD, John C. Byrd, MD, Kristie A. Blum, MD

Blood (2010) 116 (21): 57.

https://doi.org/10.1182/blood.V116.21.57.57

Published: 2010

Journal Articles

The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals

Sarah E.M. Herman, Amber L. Gordon, Emilia Mahoney, MD, PhD, Samantha M. Jaglowski, MD, Kristie A. Blum, MD, Joseph Buggy, PhD, Ahmed Hamdy, MD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2010) 116 (21): 1385.

https://doi.org/10.1182/blood.V116.21.1385.1385

Published: 2010

Journal Articles

The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study

Nathan Fowler, MD, Jeff Porte Sharman, MD, Sonali M Smith, MD, Thomas Boyd, MD, Barbara Grant, MD, Kathryn S. Kolibaba, MD, Richard R. Furman, MD, Joseph Buggy, David Loury, PhD, Ahmed Hamdy, Ranjana Advani, MD

Blood (2010) 116 (21): 964.

https://doi.org/10.1182/blood.V116.21.964.964

Published: 2010

Journal Articles

Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo.

Sabine Ponader, PhD, Joseph Buggy, PhD, Susan O'Brien, BA, MD, William G. Wierda, MD, PhD, Michael Keating, MD, Jan A. Burger, MD, PhD

Blood (2010) 116 (21): 45.

https://doi.org/10.1182/blood.V116.21.45.45

Published: 2010

Journal Articles

Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB-Mediated Pathways.

Savita Bhalla, PhD, Kevin David, MD, Lauren Mauro, MD, Sheila Prachand, MS, Mint Sirisawad, Sriram Balasubramanian, PhD, Richard A. Miller, MD, Joseph Buggy, PhD, Leo I. Gordon, MD, Andrew M. Evens, DO, MS

Blood (2007) 110 (11): 3589.

https://doi.org/10.1182/blood.V110.11.3589.3589

Published: 2007

Journal Articles

Histone Deacetylase Inhibitor, PCI-24781, Induces Growth Inhibition and Apoptosis in Hematopoietic Tumor-Derived Cell Lines and Primary Leukemia Cells.

Joseph Buggy, PhD, Sriram Balasubramanian, PhD, Jason Ramos, PhD, Mint Sirisawad, MS, Louie Naumovski, MD, PhD

Blood (2006) 108 (11): 4399.

https://doi.org/10.1182/blood.V108.11.4399.4399

Published: 2006

NARROW

The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies

The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals

The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study

Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo.

Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB-Mediated Pathways.

Histone Deacetylase Inhibitor, PCI-24781, Induces Growth Inhibition and Apoptosis in Hematopoietic Tumor-Derived Cell Lines and Primary Leukemia Cells.

Email alerts

ASH Publications

American Society of Hematology

The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies

The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals

The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study

Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo.

Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB-Mediated Pathways.

Histone Deacetylase Inhibitor, PCI-24781, Induces Growth Inhibition and Apoptosis in Hematopoietic Tumor-Derived Cell Lines and Primary Leukemia Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only